Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report

Steffen Naegel; Philipp Burow; Dagny Holle; Dietrich Stoevesandt; Simon Heintz; Annemarie Thaele; Stephan Zierz; Torsten Kraya

doi:10.1111/head.14101

Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report

Headache. 2021 Apr;61(4):694-696. doi: 10.1111/head.14101. Epub 2021 Mar 29.

Authors

Steffen Naegel¹, Philipp Burow¹, Dagny Holle², Dietrich Stoevesandt³, Simon Heintz¹, Annemarie Thaele¹, Stephan Zierz¹, Torsten Kraya^{1

4}

Affiliations

¹ Department of Neurology, Martin Luther University Halle-Wittenberg, University Hospital Halle, Halle (Saale), Germany.
² Department of Neurology, West German Headache Center, University of Duisburg-Essen, Essen, Germany.
³ Department of Radiology, Martin Luther University Halle-Wittenberg, University Hospital Halle, Halle (Saale), Germany.
⁴ Department of Neurology, St. Georg Hospital Leipzig, Leipzig, Germany.

PMID: 33779998
DOI: 10.1111/head.14101

No abstract available

Keywords: calcitonin gene-related peptide; calcitonin gene-related peptide receptor antibody; erenumab; lactate acidosis; mitochondria; mitochondrial encephalopathy; stroke-like episodes.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Calcitonin Gene-Related Peptide Receptor Antagonists / adverse effects
Calcitonin Gene-Related Peptide Receptor Antagonists / therapeutic use
Female
Humans
MELAS Syndrome / complications*
Migraine Disorders / prevention & control*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
erenumab